Skip to main content

Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial.

Publication ,  Journal Article
Butler, J; Stebbins, A; Melenovský, V; Sweitzer, NK; Cowie, MR; Stehlik, J; Khan, MS; Blaustein, RO; Ezekowitz, JA; Hernandez, AF; Lam, CSP ...
Published in: Circ Heart Fail
June 2022

BACKGROUND: We examined the effects of vericiguat compared with placebo in patients with heart failure with reduced ejection fraction enrolled in VICTORIA (Vericiguat Global Study in Patients With Heart Failure With Reduced Ejection Fraction) on health status outcomes measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) and evaluated whether clinical outcomes varied by baseline KCCQ score. METHODS: KCCQ was completed at baseline and 4, 16, and 32 weeks. We assessed treatment effect on KCCQ using a mixed-effects model adjusting for baseline KCCQ and stratification variables. Cox proportional-hazards modeling was performed to evaluate the effect of vericiguat on clinical outcomes by tertiles of baseline KCCQ clinical summary score (CSS), total symptom score (TSS), and overall summary score (OSS). RESULTS: Of 5050 patients, 4664, 4741, and 4470 had KCCQ CSS (median [25th to 75th], 65.6 [45.8-81.8]), TSS (68.8 [47.9-85.4]), and OSS (59.9 [42.0-77.1]) at baseline; 94%, 88%, and 82% had data at 4, 16, and 32 weeks. At 16 weeks, CSS improved by a median of 6.3 in both arms; no significant differences in improvement were seen for TSS and OSS between the 2 groups (P=0.69, 0.97, and 0.13 for CSS, TSS, and OSS). Trends were similar at 4 and 32 weeks. Vericiguat versus placebo reduced cardiovascular death or heart failure hospitalization risk similarly across tertiles of baseline KCCQ CSS, TSS, and OSS (interaction P=0.13, 0.21, and 0.65). CONCLUSIONS: Vericiguat did not significantly improve KCCQ scores compared with placebo. Vericiguat reduced the risk of cardiovascular death or heart failure hospitalization across the range of baseline health status. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02861534.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circ Heart Fail

DOI

EISSN

1941-3297

Publication Date

June 2022

Volume

15

Issue

6

Start / End Page

e009337

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Stroke Volume
  • Quality of Life
  • Pyrimidines
  • Humans
  • Heterocyclic Compounds, 2-Ring
  • Heart Failure
  • Cardiovascular System & Hematology
  • 3208 Medical physiology
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Butler, J., Stebbins, A., Melenovský, V., Sweitzer, N. K., Cowie, M. R., Stehlik, J., … VICTORIA Study Group, . (2022). Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. Circ Heart Fail, 15(6), e009337. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009337
Butler, Javed, Amanda Stebbins, Vojtěch Melenovský, Nancy K. Sweitzer, Martin R. Cowie, Josef Stehlik, Muhammad Shahzeb Khan, et al. “Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial.Circ Heart Fail 15, no. 6 (June 2022): e009337. https://doi.org/10.1161/CIRCHEARTFAILURE.121.009337.
Butler J, Stebbins A, Melenovský V, Sweitzer NK, Cowie MR, Stehlik J, et al. Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. Circ Heart Fail. 2022 Jun;15(6):e009337.
Butler, Javed, et al. “Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial.Circ Heart Fail, vol. 15, no. 6, June 2022, p. e009337. Pubmed, doi:10.1161/CIRCHEARTFAILURE.121.009337.
Butler J, Stebbins A, Melenovský V, Sweitzer NK, Cowie MR, Stehlik J, Khan MS, Blaustein RO, Ezekowitz JA, Hernandez AF, Lam CSP, Nkulikiyinka R, O’Connor CM, Pieske BM, Ponikowski P, Spertus JA, Voors AA, Anstrom KJ, Armstrong PW, VICTORIA Study Group. Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. Circ Heart Fail. 2022 Jun;15(6):e009337.

Published In

Circ Heart Fail

DOI

EISSN

1941-3297

Publication Date

June 2022

Volume

15

Issue

6

Start / End Page

e009337

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Stroke Volume
  • Quality of Life
  • Pyrimidines
  • Humans
  • Heterocyclic Compounds, 2-Ring
  • Heart Failure
  • Cardiovascular System & Hematology
  • 3208 Medical physiology
  • 3201 Cardiovascular medicine and haematology